MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s11060-025-05020-1

Медицинская библиотека · Journal of neuro-oncology · 2025

Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104.

Nakhate Vihang, Ly Ina, Muzikansky Alona, Rapalino Otto, Allen Jeffrey C, Blakeley Jaishri O, Campian Jian L, Clapp D Wade, Dhall Girish, Jain Rakesh K, Karajannis Matthias A, Packer Roger J, Tonsgard James, Ullrich Nicole J, Korf Bruce R, Fisher Michael J, Plotkin Scott R, Neurofibromatosis Clinical Trials Consortium

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

PURPOSE: Bevacizumab treatment is associated with imaging and hearing responses in progressive vestibular schwannoma (VS) caused by NF2-related schwannomatosis (NF2-SWN). However, its effect on co-existing intracranial non-vestibular schwannomas (NVS) and meningiomas is unclear.

METHODS

We retrospectively analyzed tumor volumes of non-target intracranial NVS and meningiomas in patients with NF2-SWN and progressive VS who were prospectively treated with bevacizumab for two years on the Neurofibromatosis Clinical Trials Consortium (NFCTC) trial NF104 (NCT01767792). Radiographic response (RR) or progression (PD) were defined as ≥ 20% decrease or ≥ 20% increase in tumor volume compared to baseline, respectively. All other responses were defined as stable disease.

RESULTS

A total of 40 meningiomas in eight patients and 12 NVS in six patients were evaluated across 22 enrolled trial participants. On best response analysis, RR occurred in 13% (5/40) of meningiomas and in 42% (5/12) of NVS. On a per-patient basis, RR for meningioma occurred in 38% (3/8) of patients and for NVS in 67% (4/6) of patients. RR in two NVS were durable throughout the study period. During two years of treatment, PD occurred in 55% (22/40) of meningiomas and in 8% (1/12) of NVS. Median time to tumor progression was 15 months for meningiomas and was not reached for NVS.

CONCLUSIONS

We observed greater activity of bevacizumab against intracranial NVS compared to meningioma, evidenced by more favorable RR rates, durability of response, and rates of PD. Potential biological differences between meningiomas and schwannomas that underlie this differential response to bevacizumab warrant further investigation.

Для цитирования: Nakhate Vihang, Ly Ina, Muzikansky Alona, Rapalino Otto, Allen Jeffrey C, Blakeley Jaishri O, Campian Jian L, Clapp D Wade, Dhall Girish, Jain Rakesh K, Karajannis Matthias A, Packer Roger J, Tonsgard James, Ullrich Nicole J, Korf Bruce R, Fisher Michael J, Plotkin Scott R, Neurofibromatosis Clinical Trials Consortium. Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104.. Journal of neuro-oncology. 2025. DOI: 10.1007/s11060-025-05020-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.